The long-patch mismatch repair pathway contributes to the cytotoxic effect of methylating agents and loss of this pathway confers tolerance to DNA methylation damage. Two methylation-tolerant mouse cell lines were identified and were shown to be defective in the MSH2 protein by in vitro mismatch repair assay. A normal copy of the human MSH2 gene, introduced by transfer of human chromosome 2, reversed the methylation tolerance. These mismatch repair defective mouse cells together with a fibroblast cell line derived from an MSH2 -/-mouse, were all as resistant to N-methyl-N-nitrosourea as repair-defective human cells. Although long-patch mismatch repair-defective human cells were 50-to 100-fold more resistant to methylating agents than repair-proficient cells, loss of the same pathway from mouse cells conferred only a 3-fold increase. This discrepancy was accounted for by the intrinsic N-methyl-N-nitrosourea resistance of normal or transformed mouse cells compared with human cells. The Ͼ20-fold differential resistance between mouse and human cells could not be explained by the levels of either DNA methylation damage or the repair enzyme O 6 -methylguanine-DNA methyltransferase. The resistance of mouse cells to N-methyl-N-nitrosourea was selective and no crossresistance to unrelated DNA damaging agents was observed. Pathways of apoptosis were apparently intact and functional after exposure to either N-methyl-N-nitrosourea or ultraviolet light. Extracts of mouse cells were found to perform 2-fold less long-patch mismatch repair. The reduced level of mismatch repair may contribute to their lack of sensitivity to DNA methylation damage.
Introduction
Mismatch repair defects are associated with human cancer. In the hereditary non-polyposis colorectal cancer (HNPCC) syndrome, germ-line mutations in one allele of four mismatch repair genes, hMSH2, hMLH1, hPMS2 (reviewed in ref. 1 
) or
Abbreviations: bzGua, O 6 -benzylguanine; DMSO, dimethyl sulphoxide; ES, embryonic stem; FISH, fluorescence in situ hybridization; HNPCC, hereditary non-polyposis colorectal cancer; MGMT, O 6 -methylguanine-DNA methyltransferase; MNNG, N-methyl-NЈ-nitro-N-nitrosoguanidine; MNU, N-methyl-N-nitrosourea; O 6 -meGua, O 6 -methylguanine; PBS, phosphatebuffered saline; SDS, sodium dodecyl sulphate; UV, ultraviolet; 3-meAde, 3-methyladenine. hMSH6 (2) confer a predisposition to colorectal and other malignancies. In the tumours that arise in HNPCC individuals, the second allele is inactivated, generally by a somatic mutation, and the tumour cells are defective in mismatch correction. Repair defects are also observed among apparently sporadic tumours. In these cases, loss of mismatch repair may arise through mutations in the hMSH3 gene (3) in addition to the genes involved in HNPCC. All these mismatch repair proteins participate in a 'long-patch' repair pathway, which corrects replication errors by replacing a substantial tract of newly synthesized DNA containing the mispair (reviewed in ref. 4) . hMSH2:hMSH6 and hMSH2:hMSH3 heterodimers, known as hMutSα (5) and hMutSβ (6) , respectively, perform mismatch recognition. hMLH1 and hPMS2 form a third heterodimer, hMutLα (7) , which interacts with hMutSα and hMutSβ and is presumably required to facilitate correction. Thus, hMSH2, hMLH1 and hPMS2 are all apparently essential for long-patch mismatch repair.
In addition to its role as an editor of DNA replication, mismatch repair contributes to cell killing by some DNA damaging drugs (reviewed in ref. 8) . The cytotoxicity of methylating agents such as N-methyl-N-nitrosourea (MNU), Nmethyl-NЈ-nitro-N-nitrosoguanidine (MNNG) or their clinical counterparts, dacarbazine and temozolomide, is largely caused by their ability to introduce O 6 -methylguanine (O 6 -meGua) into DNA (reviewed in ref. 9) . Two opposing DNA repair functions influence the lethality of this methylated base. A specific repair protein, O 6 -meGua-DNA methyltransferase (MGMT) counteracts the lethal effects of O 6 -meGua by catalysing its in situ demethylation (reviewed in ref. 10 ). In contrast, mismatch repair potentiates death by O 6 -meGua. Most cells are protected against DNA O 6 -meGua by MGMT but their resistance can be abolished by a specific MGMT inhibitor, O 6 benzylguanine (O 6 -bzGua) (11, 12) . Mex -cells, which do not express detectable MGMT, are very sensitive to methylating agents. Thus, persistent DNA O 6 -meGua is normally lethal. In contrast, mismatch repair-defective human cells are, without known exception, insensitive to the lethal effects of persistent O 6 -meGua. This resistance, known as methylation tolerance (13) , is independent of MGMT and is retained even when the MGMT is inactivated by O 6 -bzGua (14) . Tolerance can be conferred by defects in hMSH2 (14) , hMSH6 (15) (16) (17) , hMLH1 (17, 18) or hPMS2 (19) . Current models for the involvement of mismatch repair in the lethality of methylating agents suggest that the hMutSα and hMutLα complexes recognize incorrigible O 6 -meGua-containing base pairs. This recognition may lead to lethal processing (13) and/or to the direct activation of a cell cycle checkpoint (20, 21) . Because mismatch repairdefective Mex -human cells are 50-to 100-fold more resistant to MNU or MNNG than their repair proficient counterparts, selection for drug resistance has been used to isolate human cell lines that are deficient in this repair pathway (17, 22) .
Mice in which one or both copies of a mismatch repair gene are inactive have been generated by targeted gene disruption 
Materials and methods

Chemicals
All chemicals were obtained from Sigma (St Louis, MO) unless otherwise indicated. MNU was dissolved in dimethyl sulphoxide (DMSO) and diluted in phosphate-buffered saline (PBS)/20 mM HEPES, pH 7.4, to the required concentrations immediately before use. A stock solution of O 6 -bzGua (a kind gift from Dr J.Thomale, University of Essen, Germany) was prepared in DMSO and stored at -20°C. Anti-hMSH6 antiserum was a kind gift from Professor Josef Jiricny (University of Zurich, Switzerland). Antibody against hMSH2 was obtained from Santa Cruz Biotechnologies (Santa Cruz, CA), and against hMLH1 and hPMS2 from Pharmingen (San Diego, CA).
Cell culture, survival determination and selection for methylation tolerance
The cell lines used in this study are listed in Table I . All of the starting cell lines were from the ICRF Cell Production (Clare Hall, UK) stocks except for A2780 and RH95021, which were kindly provided by Dr Robert Brown, University of Glasgow, UK, and Dr Hein te Riele, Amsterdam Cancer Centre, The Netherlands, respectively. All the tumour cell lines were cultured in Dulbecco's modified minimal essential medium (Gibco BRL, Gaithersburg, MD) supplemented with 10% fetal calf serum, penicillin (100 U/ml) and streptomycin (100 µg/ml) (complete medium). Cultures were incubated at 37°C in 5% CO 2 and 95% relative humidity. Survival after treatment with DNA damaging agents was determined by clonogenic assay as previously described (22) . Cells at clonal density (100-400 cell/60 mm dish) were treated 18 h after seeding with ultraviolet light (UV), γ radiation or MNU (30 min at 37°C in PBS/20 mM HEPES, pH 7.4). Cultures were then washed, fed with complete medium and 1-2 weeks later surviving colonies were fixed with methanol, stained with Giemsa and counted. Experiments of MNU survival with A2780 or NIH3T3 cells were carried out both in the absence and in the presence of 25 µM O 6 -bzGua. In this case cell cultures were pre-treated for 2 h with the MGMT inhibitor, which was also included in the complete medium for the next 3 days. The fold increase in resistance was calculated as the ratio of respective D 37 values.
Selection of MNNG-resistant variants of Colo26 was carried out as previously described (22) . Briefly, separate cultures of exponentially growing cells were treated with 0.67 µM MNNG on day 1, 1 µM on day 3, 1.7 µM 206 on day 9 and 2.3 µM on day 12. Surviving cells were isolated by single cell cloning.
MNU-resistant derivatives of A2780 were isolated by exposing cells to a single concentration of MNU (2 mM) in the presence of O 6 -bzGua (see above). Surviving cells were isolated by single cell cloning. MGMT assay MGMT activity in cell extracts was determined using [ 3 H]MNU-treated DNA as previously described (29) or by measurement of transfer of 3 H radioactivity to proteinase K-sensitive form. The limit of detection of the latter assay corresponded to~0.03 units (pmole methyl groups per mg protein). Cell lines expressing Ͻ0.05 units of MGMT were considered to be Mex -.
DNA alkylation
Approximately 2ϫ10 8 exponentially growing Colo26, MNUcolo5, CMT167, HeLa and A2780 cells were each suspended in 10 ml serum-free growth medium. [ 3 H]MNU (20 Ci/mmol, 5 mCi/ml in ethanol; Amersham International, Amersham, UK) was added to a final concentration of 0.1 mCi/ml. After incubation at 37°C for 60 min, cells were harvested by centrifugation, washed twice by pelleting and resuspension in 10 ml growth medium followed by a further wash in 10 ml PBS. Washed cells were suspended in 10 ml TE pH 8.0 and lysed by the addition of 0.2% sodium dodecyl sulphate (SDS)/1 mM EDTA. The viscosity of the lysate was reduced by shearing through a 19 g needle and 20 µg/ml RNase was added. After a 30 min incubation at 37°C, 50 µg/ml proteinase K was added and incubation continued for a further 60 min. After three phenol extractions, DNA was precipitated with ethanol, the concentration estimated from A 260 , hydrolysed in 0.1 N HCl (30 min, 70°C) and the radioactivity of the hydrolysates was determined by scintillation counting.
Mismatch repair assay
Substrates. Mismatched heteroduplexes were constructed from molecules derived by subcloning a 211 bp PvuI-PstI fragment of HK7 M13 (30) into the pBK-CMV phagemid (Stratagene, Cambridge, UK). The inserted region contains the 'heteroduplex cassette' sequence that can be used to generate specific mismatches that inhibit restriction endonuclease cleavage. The standard substrate contained a T:C mispair in which the T was in the interrupted (c) strand and the C was located in the closed viral (v) strand. This mismatch was efficiently corrected in a long-patch, nick-dependent manner by extracts of human cells to regenerate an MluI restriction site (17) .
To construct the substrate, purified RFI closed circular duplexes containing T at position 1030 were linearized by digestion with NdeI, denatured and annealed to an excess of viral DNA containing C at position 1030. The annealed products contain a single mispair, which is 580 bp 5Ј to a unique nick ( Figure 1A ). The nicked circular molecules were purified by electroelution from agarose gels. (A small amount of re-annealed duplex was present in most substrate preparations. The restriction endonuclease digestion products of this contaminant are well resolved from the diagnostic repair products and do not interfere with the assay.) After incubation with cell extract, DNA molecules are recovered and digested with MluI. Uncorrected substrate molecules contain a single MluI site (position 463). Cleavage of the restored MluI site at position 1030 of the corrected molecules produces a diagnostic fragment of 3.9 kb, which is well resolved from the uncorrected molecules that remain unit length (4.47 kb).
A control substrate in which a small gap replaced the mispair was constructed in a similar fashion. Purified RFI-closed circular duplexes were digested with MluI and SacI (position 1070). The resulting 3.8 kb fragments were then annealed to an excess of viral molecules as above. The resulting gapped-circular duplexes ( Figure 1B ), which contain a 607 base gap, were purified by agarose gel electrophoresis. Gap-filling and ligation generates duplex molecules with two MluI sites in the same positions as in the corrected mispaired substrate. After incubation with the cell extract under conditions identical to the mismatch repair assays, recovered molecules were assayed for sensitivity to cleavage by MluI as above. Gap-filling to regenerate the two MluI sites was rapid. Activity was assessed by the appearance of the diagnostic 3.9 kb DNA fragment. Measurements were carried out in the range for which the gap-filling reaction was linear with respect to time and extract concentration.
Mismatch correction assay.
Extracts for mismatch correction assays were 207 prepared from 1-5ϫ10 9 exponentially growing cells and assays were carried out as previously described (17) . Reactions (25 µl) contained 30 mM Hepes KOH, pH 8.0, 7 mM MgCl 2 , 0.5 mM dithiothreitol, 0.1 mM dNTP, 4 mM ATP, 40 mM phosphocreatine, 1 mg creatine phosphokinase (rabbit muscle type I), 80 ng mismatched or gapped DNA substrate and up to 200 µg cell extract. After a 60 min incubation at 37°C, reactions were terminated by the addition of 10 mM EDTA, 0.5% SDS. DNA was recovered from the reaction mixture and digested with the appropriate diagnostic restriction endonuclease. Digestion products were separated on 0.8% agarose gels in TAE buffer containing ethidium bromide and visualized under short wavelength UV light. Gap-filling assays were carried out in an identical fashion except that the incubation time was reduced to 5 min. Products of the correction and gapfilling assays were quantified by scanning with a Gel-Doc system (BioRad, Hercules, CA) of the agarose gels. The data were processed by the computer program Molecular Analyst (Bio-Rad).
Western blotting
Cell extracts (150 µg) were denatured and separated on 8% SDS polyacrylamide gels. Proteins were transferred to nylon membranes, blocked by immersion in TBS-Tween (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween 80) containing 5% skimmed powdered milk. The blocked filter was incubated with primary antibody (1 µg/ml for hPMS2 and hMLH1, 0.1 µg/ ml for hMSH2 or 1:1000 diluted antiserum for hMSH6) for 1 h at room temperature. After washing with TBS-Tween the appropriate secondary antibody was added. The blots were developed using the ECL detection reagents (Amersham International).
Microcell transfer and fluorescence in situ hybridization (FISH)
The method for microcell chromosome transfer was slightly modified (31) from the one already described (32) . Briefly, micronuclei of the monochromosomal hybrid A9 cells (8ϫ10 5 ) were induced by treatment for 2 days with 0.06 µg/ml Colcemid (Sigma). The flasks were filled with serum-free DMEM containing 20 µg/ml cytochalasin B (Sigma) and placed into Sorval GSA rotor wells filled with warm water (30°C). The flasks were centrifuged at 7000 r.p.m. for 75 min at 34°C. The microcells were resuspended in DMEM and filtered through 8 and 5 µm polycarbonate filters (Nucleopore, Pleasanton, CA). The microcells were pelleted by centrifugation at 1400 r.p.m. for 20 min at 4°C and resuspended in medium containing 100 µg/ml phytohaemaglutinin (Sigma). The microcells were attached to recipient monolayers by incubation for 20 min at room temperature. The cultures were treated with 47% polyethylene glycol (M r 1450; Sigma) for 1 min, extensively washed in serumfree medium and 24 h later seeded in selective medium (1 mg/ml G418). The G418 resistant microcell hybrids were isolated after 14 days of growth.
Slides for cytogenetic analysis were prepared according to standard procedures. Briefly, mitotic figures were accumulated by treatment with 4ϫ10 -7 M Colcemid (Sigma) and washed three times with methanol:acetic acid (3:1). FISH was performed using a biotinylated probe (Oncor, Gaithesburg, MD) for the alphoid sequences of human chromosome 2. Molecular hybridization and immuno-fluorescence detection of the probes were carried out according to the protocol provided by the manufacturer. Detection of the biotin-labelled probe was performed with fluoresceinated-avidin (FITC-avidin; Vector, Burlingame, CA) and the intensity of fluorescence was amplified by a biotinylated anti-avidin antibody (Boehringer Mannheim, Mannheim, Germany) followed by an additional layer of FITC-avidin. Slides were counterstained with propidium iodide. Two hundred nuclei per clone were analysed and the number of signals in each nucleus recorded.
TUNEL analysis
Cytospin preparations of 2ϫ10 4 cells were air dried and fixed with formaldehyde (4% in PBS, pH 7.4) for 30 min at room temperature. Slides were incubated for 2 min on ice in a permeabilizing solution containing 0.25% Triton X-100 (Bio-Rad) and 0.1% sodium citrate. TUNEL assay was performed using the in situ Cell Death Detection kit, Fluorescein (Boehringer Mannheim) according to the manufacturer's instructions. Hoechst 33342 (1 µg/ml in PBS) was used to counterstain nuclei.
Results
MNU-tolerant mouse cell lines
Several independent variants of the Colo26 mouse colon carcinoma cell line with a stable resistance to MNU were selected by treatment with escalating concentrations of MNNG. One example, MNUcolo5, is shown in Figure 2A . Both Colo26 and MNUcolo5 cells are essentially Mex -and express extremely low levels of MGMT (Table I) tolerance. The degree of tolerance was modest and MNUcolo5 were only 3-fold more resistant than the Colo26 parental cells. MNUcolo5 was typical of the MNNG resistant Colo26 clones, however, and attempts to select variants with significantly higher resistance using different protocols were unsuccessful. MNUcolo5 appears to represent close to the maximum resistance attainable using this type of selection.
Since it is well established that methylation tolerance in human cells arises by loss of mismatch repair, we compared the MNU resistance of MNUcolo5 with that of a known mismatch repair-defective mouse cell line. RH95021 fibroblasts are an E1A-transformed cell line derived from a mouse bearing a homozygous targeted inactivation of the MSH2 gene (23) . The MNU resistance of RH95021 cells was similar to that of 208 MNUcolo5 (Figure 2A ). Since the RH95021 cells are Mex ϩ (Table I) , their survival was measured in the presence and absence of the MGMT inhibitor, O 6 -bzGua. O 6 -bzGua did not detectably alter the sensitivity of RH95021 to MNU (data not shown). This is consistent with a methylation-tolerant phenotype derived from their MSH2 -/-genotype. Thus, methylation tolerance in two separate mouse cell lines is associated with similar levels of MNU resistance.
To investigate whether the level of resistance of Colo26 cells was typical of mouse cells, we examined two other cell lines, B16, a Mex -mouse melanoma, and NIH3T3, a Mex ϩ non-transformed mouse embryonic fibroblast cell line (Table I) A fourth mouse cell line, CMT167, derived from a lung carcinoma, expressed MGMT levels that were close to the lower limit of detection (Table I ). Despite this, CMT167 was significantly more resistant than Colo26 to MNU ( Figure 2B ) and was comparable to MNUcolo5 and to MSH2 -/-RH95021 cells in this regard. The MNU resistance and extremely low levels of MGMT expressed by CMT167 suggested that CMT167 is a naturally methylation-tolerant tumour cell line.
MNU-tolerant human cell lines
In order to compare these results with methylation-tolerant human cells, we used tolerant variants of the HeLaMR and A2780 cell lines. HeLaMR cells are Mex -and are very sensitive to MNU. The previously described methylationtolerant derivative, HeLaClone 6 (22), is~100-fold more resistant to this agent ( Figure 2C , Table I ). The ovarian carcinoma cell line A2780 is Mex ϩ and is resistant to MNU ( Figure 2C , Table I ). When A2780 cells were treated with MNU in the presence of O 6 -bzGua, they exhibited the expected hypersensitivity of MGMT-depleted human cells and were similar to HeLaMR cells ( Figure 2C , Table I ). Methylationtolerant variants of A2780 were selected by treatment with MNU. These variants had become highly resistant to MNU in the presence of O 6 -bzGua, as expected for a typical methylation-tolerant human cell line. One example, MNUA2780, is shown in Figure 2C . The MNU resistance of both MNUA2780 and HeLaClone 6 fell within the expected range for methylation-tolerant human cells ( Figure 2C , light grey shaded sector). There are two notable features of the data presented in Figure 2 . Firstly, the MNU resistance of the methylation-tolerant mouse and human cell lines is similar. Secondly, the three mouse cell lines are significantly (ജ20-fold) more MNU resistant than both the human cell lines when the contribution of MGMT is abolished by O 6 -bzGua treatment ( Figure 2C , dark grey shaded sector).
In summary, we observed major differences between mouse and human cells in their response to a methylating agent. First, human cells were much more sensitive to killing than mouse cells. Despite this large (~20-fold) difference, methylationtolerant mouse and human cells were similar in their sensitivity to MNU.
Mismatch repair activities in cell extracts
Extracts of Colo26 cells corrected several different mispairs (including T:G, A:C, A:G and A:A) in a nicked circular duplex substrate. Repair of a T:C mismatch was typical and an example is shown in Figure 3 . Correction was directed to the nicked strand of the duplex, and little or no correction of the intact strand was observed (data not shown). This activity was absent in extracts of RH95021 mouse fibroblasts, which are MSH2 -/-. Repair of the T:C mismatch in this substrate is therefore by the MSH2-dependent long-patch, nick-directed repair pathway. Consistent with their methylation-tolerant phenotype, extracts of MNUcolo5 and CMT167 did not detectably correct the mispair and resembled MSH2-defective RH95021 cells in this regard. Extracts of MNUcolo2, a variant that had received an identical MNNG treatment but retained normal MNU sensitivity (Table I) , were fully repair-proficient and were comparable to Colo26. Methylation-tolerant HeLaClone 6 (33) and MNUA2780 extracts were also deficient in 209 Fig. 3 . Correction of a T:C mismatch in vitro. Extracts (100 µg) of mouse (Colo26, MNUcolo2 and MNUcolo5, CMT167 and the MSH2 -/-RH95021) and human (A2780 and MNUA2780) cell lines were incubated with the substrate shown in Figure 1A . Correction of the T:C mismatch generates a second MluI site that is diagnostic for repair. The arrow indicates the position of the 3.9 kb diagnostic repair fragment. mismatch correction whereas extracts of their parental HeLaMR (data not shown) and A2780 cells efficiently repaired the mismatch (Figure 3) .
Thus, as in human cells, methylation tolerance in mouse cells is associated with loss of the long-patch, nick-directed mismatch repair pathway.
Identification of the mismatch repair defects
Mismatch correction was not restored by mixing extracts of MNUcolo5 and CMT167 ( Figure 4A ), suggesting that their repair defects lie in the same protein or protein complex. Addition of extracts of human HCT116 or DLD-1 cells, defective in hMLH1 and hMSH6, respectively, partially complemented both MNUcolo5 and CMT167. Neither extract was complemented by Jurkat or LoVo cell extracts in which neither the hMSH2 (34) nor hMSH6 protein is detectable ( Figure 4A and data not shown). HCT116, but not LoVo, Jurkat or DLD-1 extracts, also complemented the repair defect in RH95021 ( Figure 4A ). This is in agreement with the absence of detectable MSH2 or MSH6 protein in RH95021 extracts as determined by western blotting (data not shown).
These data suggest that human and mouse proteins can participate in the same correction pathway, presumably by forming functional interspecies heterodimers, and that functional repair proteins in HCT116 or DLD-1 can replace the defective factors in MNUcolo5, CMT167 and RH95021. Complementation by DLD-1, but not by LoVo or Jurkat, cell extracts suggests that the MSH2 protein is defective in the methylation-tolerant MNUcolo5 and CMT167 cells.
Western blotting indicated that both hMLH1 and hPMS2 proteins, which were present in A2780 extracts, were undetectable or significantly reduced in extracts of MNUA2780 cells. hMSH2 and hMSH6 levels were comparable in the two cell lines ( Figure 4B ). The methylation-tolerant phenotype of MNUA2780 therefore results from a defect in the hMutLα complex.
Thus, complementation of the mismatch repair defects of CMT167 and MNUcolo5 indicates that their methylation tolerance is the result of a defect in the MutSα complex, most likely a mutation in MSH2. Analysis by western blotting indicates that MNUA2780 cells are methylation-tolerant because they are deficient in the hMutLα complex.
Reversion of methylation tolerance in mouse cells by transfer of human chromosome 2
Mismatch repair defects in human tumour cell lines can be corrected by the introduction of an appropriate single chromosome (18, 35 (B) Cell extracts were separated on SDS-polyacrylamide gels, and immune complexes with hMSH6, hMSH2, hMLH1 and hPMS2 were visualized after transfer to a nitrocellulose membrane by a peroxidase conjugated anti-mouse (hPMS2 and hMLH1) or anti-rabbit (hMSH6 and hMSH2)IgG. Antisera to hMSH6 and hMSH2 were used together.
suggested a defective MutSα complex in MNUcolo5 cells. Human chromosome 2, which contains both the hMSH2 and hMSH6 genes, was introduced into MNUcolo5 by microcell fusion in order to investigate whether methylation tolerance in mouse cells could be reversed by expression of the human repair complex. The presence of the human chromosome was confirmed in G418-resistant clones of MNUcolo5 by hybridization with a human-specific centromeric probe for chromosome 2 (data not shown). One G418-resistant clone, in which 50 and 36% of the cell population showed 1 and 2 hybridization signals for the human chromosome 2, respectively, was chosen to analyse survival after MNU treatment. Figure 5 (a representative experiment of three) shows that human chromosome 2 reversed the MNU resistance in this clone to close to that of the parental Colo26 cells. These observations confirm that the human mismatch repair proteins can participate in processing of DNA methylation damage by the mouse mismatch repair pathway. Significantly, restoration of mismatch correction did not confer the level of MNU sensitivity that is characteristic of the human cells we examined.
Extent of DNA methylation in mouse and human cell lines
In order to investigate whether different levels of DNA methylation were responsible for their differential MNU sensitivity, mouse and human cells were treated with 5 µM [ 3 H]MNU for 1 h and the extent of DNA methylation was determined. Table II shows that the levels of methylation varied by only 20% among the different cell lines and there was no evidence of a systematic difference between mouse and human cells. The greater sensitivity of human cells to MNU is not therefore due to higher levels of DNA damage. In addition, the MNU resistance of MNUcolo5 and CMT167 relative to Colo26 is not due to less methylation damage.
The differences in MNU sensitivity between human and 210 mouse cells cannot therefore be explained by different levels of DNA methylation.
Cell killing by other DNA damaging agents
Since the higher MNU resistance of mouse cells is not due to less methylation of DNA, we investigated whether it reflected a general resistance to DNA damaging agents, perhaps as a result of less efficient engagement of the pathways of cell death. Loss of mismatch repair in our methylation-tolerant mouse or human cell lines was not accompanied by significant changes in sensitivity to UV or γ-radiation (Table I ). In addition, the sensitivities of Colo26 and HeLa cells to ionizing radiation were essentially identical and within the range of published values for cultured mouse and human cells. A2780 cells were somewhat radiosensitive. This may be related to their functional p53/p21 pathway (36) . The survival of Colo26 mouse cells after UV irradiation was indistinguishable from that of human HeLa or A2780 cells (Table I) . Notwithstanding the γ-radiation sensitivity of A2780, which was not accompanied by hypersensitivity to UV radiation, we conclude that the increased resistance to MNU of mouse cells does not reflect a general resistance to DNA damaging agents.
In an alternative approach, we determined the ability of the mouse and human cells to undergo apoptosis in response to DNA damaging agents. After exposure to 25 J/m 2 UV light, Colo26, MNUcolo5 and A2780 cells underwent apoptosis to similar extents at 1 and 2 days after irradiation ( Figure 6A ). It appears that the pathway(s) of apoptosis that is engaged following UV irradiation is intact, and similar levels are triggered in the mouse and human cells.
Equitoxic concentrations of MNU resulting in 10% clonal survival induced apoptosis in both A2780 and Colo26 cells ( Figure 6B ). The rate of appearance of apoptotic cells was slow compared with UV, which is consistent with the different modes of killing by the two agents. The kinetics of MNUinduced apoptosis in Colo26 were somewhat slower than those in A2780, although at 4 days after treatment, the levels were comparable. Thus, MNU-induced DNA damage is able to engage apoptotic death in these mouse and human cells.
Mismatch repair levels
Because the differential sensitivity of the human and mouse cell lines to MNU was not readily explained by different levels of DNA damage or ability to engage death pathways, we considered the possibility that mouse cells might have a lower capacity for long-patch mismatch repair with which to process DNA O 6 -meGua. Extracts of human cells were consistently 2-to 3-fold more efficient at mismatch correction than mouse cell extracts. Typical examples of the correction assay are presented in Figure 7A . As a control, we examined the ability of the same extracts to fill a small single-stranded gap in a DNA duplex that was identical to the mismatch repair substrate except that the mismatch was replaced by a short singlestranded region. The extents of repair and gap-filling were quantitated following separation of MluI digestion products on agarose gels. The mismatch repair efficiency was normalized to the latter in order to minimize differences due to extract quality. In general, the levels of gap filling were closely similar in human and mouse cell extracts. Data derived from extracts of two mouse cell lines, Colo26 and NIH3T3, and two human lines, Raji and HeLa, are presented in Figure 7A . Figure 7B presents a comparison of Colo26 and HeLa extracts in which T:C mismatch repair is normalized to gap-filling activity. Thus, mouse cell extracts are consistently 2-to 3-fold less proficient at mismatch repair than human cell extracts. These differences are not accounted for by extract quality.
The mismatch correction activity of mouse cell extracts was reproducibly enhanced by the addition of extracts of the repair defective human cells, Jurkat, LoVo or HCT116 ( Figures 7C  and 4A ). These data are also compatible with a reduced level of mismatch repair activity in the mouse cell extracts and suggest that the limiting factor is not one of the proteins that are absent in these human cell lines. They suggest that the level of repair in mouse cells may be limited by a factor other than the availability of sufficient MutSα or MutLα.
Since active mismatch repair is essential for the cytotoxicity of DNA methylation damage, we conclude that a reduced capacity for long-patch, nick-directed mismatch repair may contribute to the relatively high MNU resistance of mouse cells.
Discussion
The cytotoxicity of persistent DNA O 6 -meGua, and the requirement for an active long-patch mismatch repair system for its expression, is now firmly established for human cells. Our results indicate that methylation-tolerant mouse cells have approximately the same MNU resistance as tolerant human cells. Methylation tolerance arises in the mouse cells in the same way as in human cells: by loss of the long-patch mismatch correction pathway. We exploited the ability of human and mouse mismatch repair factors to function in a common pathway both in vitro (by extract complementation) and in vivo (by single chromosome transfer) to demonstrate that methylation tolerance could arise through a defective murine MutSα complex.
An important difference between mouse and human cells, however, is that loss of mismatch correction in mouse cells confers only a relatively modest increase in methylation resistance. The increase is minor because mouse cells are intrinsically more refractory to killing by MNU than human cells. We observed consistently higher MNU resistance in several mouse cell lines of different types and from different genetic backgrounds. There are additional observations that suggest that discrepant methylation sensitivity is a general feature of mouse and human cells. Examples of MGMT-212 independent methylating agent resistance in mouse and hamster cells can be found in published reports (37, 38) , although the differences between rodent and human cells have gone unremarked. Mex -human and hamster cells can be protected against methylating agent cytotoxicity by expression of a transfected Escherichia coli Ada gene (the homologue of MGMT). The degree of protection afforded is, however, very different (20-to 40-fold for human cells compared with~5-fold for hamster cells) (38) (39) (40) (41) (42) . These differences cannot be ascribed to different levels of Ada gene expression. In addition, the extent of methylation tolerance in a mismatch recognitiondefective hamster cell line is modest (12-fold) in comparison with the 50-to 100-fold observed in mismatch repair-defective derivatives of human HeLa (22) , Raji (17), TK6 (15) or A2780 cells (this study).
We considered several possible factors that might influence the relative methylation resistance of mouse cells. A trivial one, that the cells sustain less potentially lethal DNA damage, is excluded by our dosimetry data, which indicate that the levels of methylation in mouse and human cells are closely comparable. These are consistent with the simple nature of the methylation reaction and the absence of any requirement for metabolic activation of MNU. In addition to O 6 -meGua, other methylated bases, which are considered potentially cytotoxic, principally 3-methyladenine (3-meAde), will also be present at similar levels in MNU-treated mouse and human cells. Although it is possible that enhanced repair of 3-at Pennsylvania State University on February 21, 2013 http://carcin.oxfordjournals.org/ Downloaded from meAde by mouse cells might contribute to their relative MNU resistance, we consider it unlikely. Repair of 3-meAde is mediated by the product of the AAG gene, a DNA glycosylase that catalyses its removal from DNA (43) . The levels of 3-meAde-DNA glycosylase are similar in human and rodent cells. They are, if anything, somewhat lower in mouse and hamster than in human cell extracts (44) (45) (46) . In addition, the complete absence of detectable 3-meAde-DNA glycosylase from AAG -/-embryonic stem (ES) cells confers only a 2-to 4-fold increase in sensitivity to methylating agents (47) . This change is small compared with the Ͼ20-fold difference in MNU resistance between mouse and human cells, and the observation supports the conclusion that different efficiencies of repair of 3-meAde are unlikely to be responsible for the relative MNU resistance of mouse cells.
Our data suggest that the MNU resistance of mouse cells is not due to defects in apoptotic pathways. Firstly, UV radiation induced similar levels of apoptosis in mouse and human cells. In addition, human and mouse cells were both susceptible to MNU-induced apoptosis, indicating that this pathway was intact and able to transduce death signals. Furthermore, we found no evidence for a systematically higher resistance to all types of DNA damage in mouse cells. With a single exception, the mouse and human cells were equally sensitive to two unrelated DNA damaging agents, UV and ionizing radiation. Finally, both MNU and γ-radiation provoke cell cycle arrest in the G2 phase. Since mouse and human cells exhibit similar sensitivity to γ-radiation, it is unlikely that the differences observed for methylation damage are due to a relaxed cellcycle checkpoint control in mouse cells.
We note that ES cells do not share the generally high resistance of differentiated mouse cells to DNA methylation damage. Although mouse ES cells without MGMT are extremely sensitive to MNNG (23, 47) , this hypersensitivity most likely reflects a general sensitivity to diverse DNA damaging agents. It has been suggested that ES cells are unusually efficient at activating apoptosis following exposure to many different types of cytotoxic agent (48) .
Since active long-patch mismatch repair is a requirement for the cytotoxicity of O 6 -meGua in human cells, the higher intrinsic resistance of rodent cells may reflect less processing of the methylated DNA base. This possibility is supported by our observation that mouse cell extracts reproducibly carried out less long-patch, nick-directed mismatch repair than their human counterparts. In addition, repair by mouse cell extracts is apparently limited by a factor that could be provided by human cell extracts but is not one of the components of the hMutSα and hMutLα complexes. The differences in repair capacity were small, however, and may not in themselves be sufficient to explain fully the relative MNU resistance of the mouse cells. An alternative possibility is that the mouse MutSα recognition factor might initiate processing of O 6 -meGua less efficiently than its human counterpart, perhaps because of a lower affinity for the incorrigible base pairs. The hMutSα complex recognizes G:T and O 6 -meGua:T base pairs (49, 50) . The affinity of mouse mismatch recognition factor(s) for O 6 -meGua-containing base pairs is unknown. We are currently addressing this question using mismatch recognition complexes purified from human and mouse cells.
Our findings have some implications for the use of mice as models of human cancer. Mice are used as hosts for human tumour xenografts to evaluate the potential of therapeutic agents. Clearly, since mouse tissues have an intrinsically higher 213 resistance to DNA methylation damage than human tumour cells, methylating agents will be less toxic to the mouse host than to a human host. The use of such agents in xenograft experiments is therefore likely to indicate an erroneously high therapeutic index, not because of a high sensitivity of the tumour but because of low toxicity to the host. In addition, knockout mice are used as models for HNPCC. If the longpatch mismatch repair pathway is less efficient in mouse cells, the phenotypes of knockout mice are likely to be an incomplete reflection of HNPCC. Such differences may contribute to the apparent absence of a significant predisposition to tumour development in mice that are heterozygous for mismatch repair defects. They might also influence the types of tumours that develop in homozygously repair-defective mice, which do not, in general, reflect the tumours in HNPCC patients.
